Medication info

Zantini Tablet 150 mg (Ranitidine Hydrochloride)

Prescription medicationTabletOralExpired
Ingredient · strength
Ranitidine Hydrochloride›168mg / 1 tablet
Manufacturer / importer
Lightpharmtech Co., Ltd.
Appearance
Off-white to pale yellow round film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Expired

MFDS item code 201902487 · Approved 2019.04.23

This product's status changed to Expired on 2024.04.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of acid-related disorders (such as ulcers), improvement of gastric mucosal lesions, and prevention of Mendelson's syndrome
Who takes it
Adults · Children
Adult dose
1. Adults Administer ranitidine 150 mg orally twice daily, in the morning and at bedtime. 1) Gastric and duodenal ulcers Administer 150 mg of this medicine orally twice daily, or 300 mg once daily at bedtime. A higher cure rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg twice daily, in the morning and at bedtime. The dosage and administration are the same when used concomitantly to treat ulcers caused by nonsteroidal anti-inflammatory drugs or to prevent gastric and duodenal ulcers during long-term administration of nonsteroidal anti-inflammatory drugs. Healing usually occurs within 4 weeks; conditions caused by nonsteroidal anti-inflammatory drugs usually heal within 8 weeks, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. 2) Reflux esophagitis Administer 150 mg of this medicine twice daily for 8 weeks, or 300 mg once daily at bedtime. The dose may be increased to 150 mg 4 times daily in patients with severe reflux esophagitis. 3) Zollinger-Ellison syndrome Initiate treatment with 150 mg of this medicine 3 times daily and increase the dose as needed. In severe cases, up to 6 g daily may be administered as directed by a physician. 4) In cases of upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, or acute gastric mucosal lesions, treatment is usually initiated with an injectable formulation. When oral administration becomes possible, switch to oral administration of 150 mg of this medicine twice daily. 5) Premedication for anesthesia (prevention of Mendelson syndrome) Administer 150 mg of this medicine 2 hours before induction of anesthesia. In this case, it is preferable to also administer 150 mg on the night before surgery. 6) Improvement of gastric mucosal lesions (erosions, bleeding, redness, edema) in the following conditions: acute gastritis and acute exacerbation of chronic gastritis Administer 150 mg of this medicine once daily at bedtime. 3. Patients with renal impairment In patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the plasma concentration of the medicine; therefore, readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.
Child dose
7) Hyperacidity, heartburn, acid regurgitation: In patients aged 12 years or older, administer 75 mg of this medicine orally twice daily (liquid formulation only). 2. Children Clinical studies in children have not been established; however, in children aged 8 〜 18 years, 150 mg (2 mg per kg of body weight) may be administered up to twice daily.

Ingredients

Manufacturer
Lightpharmtech Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (such as ulcers), improvement of gastric mucosal lesions, and prevention of Mendelson's syndrome

  • Gastric and duodenal ulcers
  • Zollinger-Ellison syndrome
  • gastroesophageal reflux disease
  • Mendelson syndrome
  • postoperative ulcers
  • ulcers due to NSAID administration
  • gastric mucosal lesions
  • erosion
  • bleeding
  • redness
  • swelling
  • acute gastritis
View approved original text

This medication is used to treat ulcers in the stomach and duodenum and is also indicated for Zollinger-Ellison syndrome. It is applicable to patients with gastroesophageal reflux disease, assists in the prevention of postoperative ulcers, and helps treat ulcers caused by the use of non-steroidal anti-inflammatory drugs (NSAIDs). Furthermore, it improves gastric mucosal lesions such as eroded areas, bleeding, redness, and swelling during acute exacerbations of acute and chronic gastritis and during upper gastrointestinal bleeding. It is effective in relieving symptoms of heartburn or acid regurgitation caused by excessive gastric acid. Overall, it is used to effectively treat various gastrointestinal diseases and symptoms.

How to take

Adult dose

1. Adults Administer ranitidine 150 mg orally twice daily, in the morning and at bedtime. 1) Gastric and duodenal ulcers Administer 150 mg of this medicine orally twice daily, or 300 mg once daily at bedtime. A higher cure rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg twice daily, in the morning and at bedtime. The dosage and administration are the same when used concomitantly to treat ulcers caused by nonsteroidal anti-inflammatory drugs or to prevent gastric and duodenal ulcers during long-term administration of nonsteroidal anti-inflammatory drugs. Healing usually occurs within 4 weeks; conditions caused by nonsteroidal anti-inflammatory drugs usually heal within 8 weeks, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. 2) Reflux esophagitis Administer 150 mg of this medicine twice daily for 8 weeks, or 300 mg once daily at bedtime. The dose may be increased to 150 mg 4 times daily in patients with severe reflux esophagitis. 3) Zollinger-Ellison syndrome Initiate treatment with 150 mg of this medicine 3 times daily and increase the dose as needed. In severe cases, up to 6 g daily may be administered as directed by a physician. 4) In cases of upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, or acute gastric mucosal lesions, treatment is usually initiated with an injectable formulation. When oral administration becomes possible, switch to oral administration of 150 mg of this medicine twice daily. 5) Premedication for anesthesia (prevention of Mendelson syndrome) Administer 150 mg of this medicine 2 hours before induction of anesthesia. In this case, it is preferable to also administer 150 mg on the night before surgery. 6) Improvement of gastric mucosal lesions (erosions, bleeding, redness, edema) in the following conditions: acute gastritis and acute exacerbation of chronic gastritis Administer 150 mg of this medicine once daily at bedtime. 3. Patients with renal impairment In patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the plasma concentration of the medicine; therefore, readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.

Child dose

7) Hyperacidity, heartburn, acid regurgitation: In patients aged 12 years or older, administer 75 mg of this medicine orally twice daily (liquid formulation only). 2. Children Clinical studies in children have not been established; however, in children aged 8 〜 18 years, 150 mg (2 mg per kg of body weight) may be administered up to twice daily.

Precautions

This drug should not be used in patients who have had hypersensitivity reactions to its components. This medication should not be administered to patients with a history of acute porphyria as it may provoke seizures. It contains lactose, hence it should not be given to patients with lactose intolerance or specific genetic problems. Patients with impaired kidney function need dosage adjustment as this drug may remain in the body for a longer period. Caution is required for patients with liver dysfunction. Patients with a history of drug allergy and the elderly should also be carefully administered this medication. Patients taking non-steroidal anti-inflammatory drugs concomitantly need to be monitored for side effects. Because this drug may mask symptoms of gastric cancer, gastric ulcer patients or older patients with new dyspeptic symptoms should be assessed for malignancy before treatment. In cases of Helicobacter pylori infection, eradication therapy should be conducted concurrently. This medication may rarely cause severe allergic reactions or shock; thus, if any unusual symptoms appear, use should be immediately discontinued and medical attention sought. Symptoms such as decreased blood cell count, liver dysfunction, arrhythmias, gastrointestinal issues, and neurological abnormalities may occur; consultation with a physician is required if these symptoms arise. Symptoms of mental confusion, blurred vision, and seizures have also been reported, necessitating caution if neurological symptoms appear. Myalgia, arthralgia, and skin rashes may also occur rarely. During treatment, the course of the disease should be closely monitored, and treatment should be conducted with the minimum effective dose. If no effect is observed, alternative treatment should be sought. The elderly, and those with chronic lung disease, diabetes, or immune compromise may experience a higher risk of pneumonia and should take care. If dizziness or drowsiness occurs after taking this medication, driving or operating dangerous machinery should be avoided. This medication may interact with other drugs; thus, if there are concomitant medications, consulting a physician or pharmacist is necessary. Especially when used with anticoagulants, bleeding risks must be closely monitored. It may also affect the absorption or excretion of certain drugs, thus necessitating adjustments in dosing times. Pregnant women or those who might become pregnant should use this medication only if the benefits outweigh the risks, and its use should also be approached with caution in breastfeeding women. The safety in children is not well established; hence caution is necessary. The elderly may have prolonged retention of the drug in the body due to decreased kidney function, requiring reduction of dosage or extension of dosing intervals. Some tests may be affected by this medication, so it is advisable to adjust the testing methods. No significant issues have been reported in cases of overdose, yet appropriate treatment such as vomiting or gastric lavage may be required. This medication should be stored out of reach of children, and transferring it to another container should be avoided as it could result in accidents or degradation of quality.

Side effects

Anaphylactic shock, urticaria, angioedema, rash, fever, bronchospasm, hypotension, chest pain, granulocytopenia, elevated serum creatinine levels, leukopenia, thrombocytopenia, bone marrow suppression, aplastic anemia, hypoplastic anemia, myelodysplastic syndrome, acquired immune hemolytic anemia, eosinophilia, general malaise, weakness, subcutaneous and mucosal bleeding, liver function impairment (elevated AST, ALT, γ-GTP, ALP levels), jaundice, hepatitis, bradycardia, atrioventricular block, tachycardia, vasculitis, constipation, nausea, vomiting, abdominal distension, abdominal pain, loss of appetite, diarrhea, acute pancreatitis, dizziness, drowsiness, convulsions, headache, heaviness of the head, insomnia, agitation, anxiety, mental confusion, depression, hallucinations, blurred vision, involuntary movement disorders, consciousness disorders, hepatic myoclonus, gynecomastia, excessive milk secretion, erectile dysfunction, decreased libido, arthralgia, myalgia, rhabdomyolysis, skin rash, erythema multiforme, alopecia, glossitis, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute interstitial nephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that blocks light, at a temperature between 1 and 30 degrees Celsius. Proper storage can help maintain its efficacy for a longer time.

Appearance and packaging

Appearance

Off-white to pale yellow round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.